ARBs inhibit the actions of angiotensin II at the tissue level by competing with this potent vasoconstrictor for binding to the angiotensin AT1-subtype receptor, the receptor that mediates the well-documented cardiovascular and renal actions attrib
uted to angiotensin II. Some of these drugs, as the corner-stone of a multidrug therapeutic regimen, have exhibited cardioprotective or renoprotective benefits in patients with a variety of chronic kidney disease or proteinuria.